Botanicals as epigenetic modulators for mechanisms contributing to development of metabolic syndrome

Metabolism: Clinical and Experimental

Volumn 57, Issue SUPPL. 1, 2008, Pages

  Kirk, Heather ^a,b   Cefalu, William T ^a   Ribnicky, David ^c   Liu, Zhijun ^b   Eilertsen, Kenneth J ^a  

^a PENNINGTON BIOMEDICAL RESEARCH CENTER   (United States)

^b LOUISIANA STATE UNIVERSITY   (United States)

^c RUTGERS UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

4 N ACETYLDINALINE; 5 AZA 2' DEOXYCYTIDINE; 5,6 DIHYDROAZACITIDINE; 6 (1,3 DIOXO 1H,3H BENZO[DE]ISOQUINOLIN 2 YL) N HYDROXYHEXANAMIDE; APICIDIN; ARACHIDONIC ACID; AZACITIDINE; BUTYRIC ACID; CURCUMIN; DEPSIPEPTIDE; DNA METHYLTRANSFERASE INHIBITOR; EPIGALLOCATECHIN GALLATE; FLUCYTOSINE DEOXYRIBOSIDE; GARCINOL; HISTONE DEACETYLASE INHIBITOR; HYDRALAZINE; MC 1626; MC 1752; MC 1823; MG 98; N (2 AMINOPHENYL) 4 (3 PYRIDINYLMETHOXYCARBONYLAMINOMETHYL)BENZAMIDE; NATURAL PRODUCT; NZ 01; OXAMFLATIN; PANOBINOSTAT; PDX 101; PLANT EXTRACT; PMI 5011; PROCAINAMIDE; RG 108; RNA DIRECTED DNA POLYMERASE INHIBITOR; TRICHOSTATIN A; VALPROIC ACID; VORINOSTAT; ZEBULARINE;

AGING; ARTICLE; BONE MARROW SUPPRESSION; BONE MARROW TUMOR; CARBOHYDRATE METABOLISM; CELL DIVISION; CELL NUCLEUS TRANSPLANTATION; CYTOLOGY; DAUGHTER CELL; DISEASE COURSE; DNA METHYLATION; DNA MODIFICATION; DNA SEQUENCE; ENVIRONMENTAL FACTOR; EPIGENETICS; FEBRILE NEUTROPENIA; GENE EXPRESSION; GENE MUTATION; GENE THERAPY; GENETIC DISORDER; GENOME; GERM LINE; HUMAN; LIFESTYLE; MEDICINAL PLANT; METABOLIC SYNDROME X; NONHUMAN; PREVALENCE; PRIORITY JOURNAL; SOMATIC CELL; STEM CELL;

ANIMALS; CARBOHYDRATE METABOLISM; DNA METHYLATION; EPIGENESIS, GENETIC; HUMANS; METABOLIC SYNDROME X; MODELS, BIOLOGICAL; PHYTOTHERAPY; PLANT EXTRACTS;

EID: 44949207656     PISSN: 00260495     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.metabol.2008.03.006     Document Type: Article

References (52)

1. Feinberg A.P., and Vogelstein B. Hypomethylation distinguishes genes of some human cancers from their normal counterparts. Nature 301 (1983) 88-92
2. Tsankova N., Renthal W., Kumar A., and Nestler E.J. Epigenetic regulation in psychiatric disorders. Nat Rev Neurosci 8 (2007) 355-367
3. Brunet A., and Rando T.A. Ageing: from stem to stern. Nature 449 (2007) 288-291
4. Oostra B.A., and Willemsen R. The X chromosome and fragile X mental retardation. Cytogenet Gen Res 99 (2002) 257-264
5. Claus R., and Lubbert M. Epigenetic targets in hematopoetic malignancies. Oncogene 22 (2003) 6489-6496
6. Maher E.R., and Reik W. Beckwith-Weideman syndrome: imprinting in cluster revisited. J Clin Invest 105 (2000) 247-252
7. Nicholls R.D., Saitoh S., and Horsthemka B. Imprinting in Prader-Willi and Angeleman syndromes. Trend Genet 14 (1998) 194-200
8. Barker D.J., Osmond C., Golding J., Kuh D., and Wadsworth M.E. Growth in utero, blood pressure in childhood and adult life, and mortality from cardiovascular disease. BMJ 298 (1989) 564-567
9. Grafi G. How cells dedifferentiate: a lesson from plants. Dev Biol 268 (2004) 1-6
10. Strahl B.D., and Allis C.D. The language of covalent histone modifications. Nature 403 (2000) 41-45
11. Razin A., and Riggs A.D. DNA methylation and gene function. Science 210 (1980) 604-610
12. Szyf M. DNA methylation and demethylation as targets for anticancer therapy. Biochemistry (Mosc) 70 (2005) 533-549
13. Goll M.G., and Bestor T.H. Eukaryotic cytosine methyltransferases. Annu Rev Biochem 74 (2005) 481-514
14. Bourc'his D., and Bestor T.H. Meiotic catastrophe and retrotransposon reactivation in male germ cells lacking Dnmt3L. Nature 431 (2004) 96-99
15. Bourc'his D., Xu G.L., Lin C.S., Bollman B., and Bestor T.H. Dnmt3L and the establishment of maternal genomic imprints. Science 294 (2001) 2536-2539
16. Wagner C., Briggs W.T., and Cook R.J. Inhibition of glycine N-methyltransferase by folate derivatives: implications for regulation of methyl group metabolisms. Bioch Biophys Res Comm 127 (1985) 746-752
17. Rowling M.J., McMullen M.H., and Schalinske K.L. Vitamin A and its derivatives induce glycine N-methyltransferase and hypomethylation of DNA in rats. J Nutr 132 (2002) 365-369
18. Rowling M.J. Retinoic acid and glucocorticoid treatment induce hepatic glycine N-methyltransferase and lowers plasma homocysteine concentrations in rats and hepatoma cells. J Nutr 133 (2003) 3392-3398
19. Wijekoon E.P., Hall B.N., Ratnam S., Brosnan M.E., Zeisel S.H., and Brosnan J.T. Homocysteine metabolism in ZDF (type w) diabetic rats. Diabetes 54 (2005) 3245-3251
20. Xue G., and Snoswell A.M. Disturbance of methyl group metabolism in alloxan-diabetic sheep. Biochem Inter 10 (1985) 897-905
21. Egger G., Liang G., Aparicio A., and Jones P.A. Epigenetics in human disease and prospects for epigenetic therapy. Nature 429 (2004) 457-463
22. Yoo C.B., and Jones P.A. Epigenetic therapy of cancer: past, present and future. Nat Rev Drug Disc 5 (2006) 37-50
23. Sorm F., Piskala A., Cihak A., and Vesely J. 5-Azacytidine, a new, highly effective cancerostatic. Experientia 20 (1964) 202-203
24. Jones P.A., and Taylor S.M. Cellular differentiation, cytidine analogs and DNA methylation. Cell 20 (1980) 85-93
25. Issa J.P., Gharibyan V., Cortes J., Jelinek J., Morris G., Verstovsek S., et al. Phase II study of low-dose decitabine in patients with chronic myelogenous leukemia resistant to imatinib mesylate. J Clin Oncol 23 (2005) 3948-3956
26. Santini V., Kantarjian H.M., and Issa J.P. Changes in DNA methylation in neoplasia: pathophysiology and therapeutic implications. Ann Intern Med 134 (2001) 573-586
27. Leone G., Voso M.T., Teofili L., and Lubbert M. Inhibitors of DNA methylation in the treatment of hematological malignancies and MDS. Clin Immunol 109 (2003) 89-102
28. Moyers S.B., and Kumar N.B. Green tea polyphenols and cancer chemoprevention: multiple mechanisms and endpoints for phase II trials. Nutr Rev 62 (2004) 204-211
29. Brueckner B., Garcia B.R., Siedlecki P., Musch T., Kliem H.C., Zielenkiewicz P., et al. Epigenetic reactivation of tumor suppressor genes by a novel small-molecule inhibitor of human DNA methyltransferases. Cancer Res 65 (2005) 6305-6311
30. Fang M.Z., Wang Y., Ai N., Hou Z., Sun Y., Lu H., et al. Tea polyphenol (-)-epigallocatechin-3-gallate inhibits DNA methyltransferase and reactivates methylation-silenced genes in cancer cell lines. Cancer Res 63 (2003) 7570-7653
31. Nakagawa H., Hasumi K., Woo J.T., Nagai K., and Wachi M. Generation of hydrogen peroxide primarily contributes to the induction of Fe (II)-dependent apoptosis in Jurkat cells by (-)-epigallacatechin gallate. Carcinogenesis 25 (2004) 1567-1574
32. Yoshida M., Kijima M., Akita M., and Beppu T. Potent and specific inhibition of mammalian histone deacetylase both in vivo and in vitro by trichostatin A. J Biol Chem 265 (1990) 17174-17179
33. Marmostein R. Structure of histone acetyl transferases. J Mol Biol 311 (2001) 433-444
34. Philips A.C., and Vousden K.H. Acetyl transferases and tumor suppression. Breast Cancer Res 2 (2000) 244-246
35. Lau O.D., Kundu T.K., Soccio R.E., Ait-Si-Ali S., Khalil E.M., Vassilev A., et al. HATs off: selective synthetic inhibition of the histone acetyl transferases p300 and PCAF. Mol Cell 5 (2000) 589-995
36. Balasubramanyam K., Swaminathan V., Ranganathan A., and Kundu T.K. Small molecule modulators of histone acetyl transferase p300. J Biol Chem 278 (2003) 19134-19140
37. Balasubramanyam K., Altaf M., Varier R.A., Swaminathan V., Ravindrin A., Sadhale P.P., et al. Polyisoprenylated benzophenone, garcinol, a natural HAT inhibitor represses chromatin transcription and alters global gene expression. J Biol Chem 279 (2004) 33716-33726
38. Balasubramanyam K., Varier R.A., Altaf M., Swaminathan V., Siddappa N.B., Ranga U., et al. Circumin, a novel p300/CREB-binding protein-specific inhibitor of acetyltransferase, represses acetylation of histone/nonhistone proteins and histone acetyltransferase-dependent chromatin transcription. J Biol Chem 279 (2004) 51163-51173
39. Biel M., Kretsovali A., Karatzali E., Papamatheakis J., and Giannis A. Design, synthesis and biological evaluation of a small molecule inhibitor of the histone acetyltransferase GCN5. Angew Chem Int Ed 43 (2004) 3975-3976
40. Stimson L., Rowlands M.G., Newbatt Y.M., Smith N.F., Raynaud F.I., Rogers P., et al. Isothiazolones as inhibitors of PCAF and p300 histone acetyltransferases. Mol Cancer Ther 4 (2005) 1521-1532
41. Ornaghi P., Rotili D., Sbardella G., Mai A., and Filetici P. A novel Gen5p inhibitor represses cell growth, gene transcription and histone acetylation in budding yeast. Biochem Pharmacol 70 (2005) 911-917
42. Mai A., Rotili D., and Ornaghi P. Identification of small molecule inhibitors of GCN5 histone acetyltransferase activity. ARKIVOC viii (2006) 24-37
43. Mai A., Rotili D., Tarantino D., Orhaghi P., Tosi F., Vicdomini C., et al. Small molecule inhibitors of histone acetyl transferase activity: identification and biological properties. J Med Chem 49 (2006) 6897-6907
44. Cameron E.E., Bachman K.E., Myohanen S., herman J.G., and Baylin S.B. Synergy of demethylation and histone deacetylation in the re-expression of genes silenced in cancer. Nat Genet 21 (1999) 103-107
45. Belinsky S.A., Klinge D.M., Stidely C.A., Issa J.P., Herman J.G., March T.H., et al. Inhibition of DNA methylation and histone deacetylation prevents murine lung cancer. Cancer Res 63 (2003) 7089-7093
46. Betthauser J.M., Pfister-Genskow M., Xu H., Golueke P.J., Lacson J.C., Koppang R.W., et al. Nucleoplasmin facilitates reprogramming and in vivo development of bovine nuclear transfer embryos. Mol Reprod Dev 73 (2006) 977-986
47. Eilertsen K.J., Power R.A., Harkins L.L., and Misica P. Targeting cellular memory to reprogram the epigenome, restore potential, and improve somatic cell nuclear transfer. Anim Reprod Sci 98 (2007) 129-146
48. Kim S.Y., Park K.W., Kim J.Y., Jeong I.Y., Byun M.W., Park J.E., et al. Thiosulfinates from Allium tuberosum L. induce apoptosis via caspase-dependent and -independent pathways in PC-3 human prostate cancer cells. Bioorg Med Chem Lett (2007) [Electronic publication ahead of print]
49. Gao D., Li Q., Li Y., Liu Z., Liu Z., Fan Y., et al. Antidiabetic potential oleanolic acid from Ligustrum lucidum Ait. Can J Physiol Pharmacol 85 (2007) 1076-1083
50. Shoemaker M., Hamilton B., Dairkee S.H., Cohen I., and Campbell M.J. In vitro anticancer activity of twelve Chinese medicinal herbs. Phytother Res 19 (2005) 649-651
51. Lin H.M., Yen F.L., Ng L.T., and Lin C.C. Protective effects of Ligustrum lucidum fruit extract on acute butylated hydroxytoluene-induced oxidative stress in rats. J Ethnopharmacol 111 (2007) 129-136
52. Sung S.H., Kim E.S., Lee K.Y., Lee M.K., and Kim Y.C. A new neuroprotective compound of Ligustrum japonicum leaves. Planta med 72 (2006) 62-64